FIELD: medicine.
SUBSTANCE: invention relates to a compound of the formula III or its pharmaceutically acceptable salt, which can be used for the treatment of neurodegenerative diseases. In the formula III, R4 is selected from H and C1-6 alkyl, and R3 is: (a) H, OH, NH2, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or 3-6-element heterocyclic ring containing one heteroatom selected from O; or (b) C1-6 alkyl optionally substituted with 1, 2 or 3 substituents, each of which is independently selected from OH, halogen, NH2, -SO2H, -SO2(C1-6 alkyl), CN or phenyl group optionally substituted with 1, 2 or 3 substituents, each of which is independently selected from a group consisting of OH; or (c) -O-C1-6 alkyl; or (d) phenyl group optionally substituted with 1, 2 or 3 substituents, each of which is independently selected from a group consisting of OH, NO2 and halogen. Proposed compounds have improved penetration through a blood-brain barrier. The invention also relates to specific compounds and a pharmaceutical composition containing the specified compounds.
EFFECT: obtaining compounds for the treatment of neurodegenerative diseases.
formula III
25 cl, 2 dwg, 1 tbl, 32 ex
Title | Year | Author | Number |
---|---|---|---|
PHENYL DERIVATIVES AND THEIR APPLICATION AS IMMUNOMODULATORS | 2007 |
|
RU2442780C2 |
SOBETIROME DERIVATIVES | 2017 |
|
RU2776372C2 |
SUBSTITUTED N-PHENYLBIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | 2008 |
|
RU2477720C2 |
BORON-CONTAINING DIACYLHYDRASINES | 2014 |
|
RU2637946C2 |
RAD51 INHIBITORS | 2018 |
|
RU2795882C2 |
NEW INHIBITORS OF ALPHA AND BETA MEPRIN | 2017 |
|
RU2746850C2 |
MODULATORS OF INTEGRATED STRESS SIGNALING PATH | 2017 |
|
RU2769327C2 |
TRANSGLUTAMINASE 2 (TG2) INHIBITORS | 2019 |
|
RU2781370C2 |
COMPOUNDS, COMPOSITIONS AND METHODS FOR INCREASING CFTR ACTIVITY | 2015 |
|
RU2767460C2 |
COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | 2007 |
|
RU2525392C2 |
Authors
Dates
2021-11-18—Published
2017-08-14—Filed